MedTrace Logo

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms

NCT02715024 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2016-03-22

No results posted yet for this study

Summary

The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms in Taiwan.

Conditions

Interventions

DRUG

Tamsulosin

Oral

DRUG

Solifenacin

Oral

Sponsors & Collaborators

  • Astellas Pharma Taiwan, Inc.

    lead INDUSTRY

Principal Investigators

  • Therapeutic Area Lead of Medical Affairs (Asia-Oceania) · Astellas Pharma Taiwan, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715024 on ClinicalTrials.gov